Compliance Rate

Compliance Rate 0%
Compliant submissions 0
Incompliant submissions 0
Total trials 0

My Organizations' Clinical Trials

Showing 175 of 1463 entries
View as:

Fruquintinib Combined With TAS-102 in the Treatment of Patients With Advanced Metastatic CRC

Phase: N/A Priority: Normal
NCT ID: NCT05004831 Org: User:
Start: 03/11/22 End: 09/30/24 Due: 09/30/25

Detection Cell Free DNA in Lung Cancer Patients

Phase: N/A Priority: Normal
NCT ID: NCT02738593 Org: User:
Start: 04/30/16 End: 10/31/18 Due: 10/31/19

PD-1 Inhibitor or PD-1 Inhibitor Plus GVD for Relapsed/Refractory CHL

Phase: N/A Priority: Normal
NCT ID: NCT04624984 Org: User:
Start: 04/01/21 End: 04/30/25 Due: 04/30/26

Mild-dose IMRT for Early-staged Extranodal Nasal-type NK/T-cell Lymphoma With CR Tumor After GELOX Chemotherapy

Phase: N/A Priority: Normal
NCT ID: NCT02229682 Org: User:
Start: 10/31/14 End: 10/31/19 Due: 10/31/20

Zimberelimab Plus Lenvatinib After Progression on Prior Immune Checkpoint Inhibitors for Advanced Cervical Cancer

Phase: N/A Priority: Normal
NCT ID: NCT05824468 Org: User:
Start: 06/01/23 End: 06/30/26 Due: 06/30/27

S-1+Oxaliplatin vs.S-1+Cisplatin First-line Treatment of Advanced or Recurrent Non-intestinal Type Gastric Adenocarcinoma Patients

Phase: N/A Priority: Normal
NCT ID: NCT01824459 Org: User:
Start: 04/30/13 End: 12/01/18 Due: 12/01/19

P-Gemox Regimen as First-line Chemotherapy in NK/T Lymphoma Patiens

Phase: N/A Priority: Normal
NCT ID: NCT02533323 Org: User:
Start: 01/31/12 End: 01/31/17 Due: 01/31/18

A Prospective Cohort Study of Advanced Colorectal Cancer Treated With Oxaliplatin and Irinotecan.

Phase: N/A Priority: Normal
NCT ID: NCT05731336 Org: User:
Start: 05/01/22 End: 05/31/26 Due: 05/31/27

Neoadjuvant Immunotherapy Plus Chemotherapy Followed by Concurrent Chemoradiotherapy and Consolidative Immunotherapy for Locally Advanced Non-small Cell Lung Cancer

Phase: N/A Priority: Normal
NCT ID: NCT06734702 Org: User:
Start: 11/30/24 End: 11/29/28 Due: 11/29/29

IV Ascorbic Acid in Advanced Gastric Cancer

Phase: N/A Priority: Normal
NCT ID: NCT03015675 Org: User:
Start: 03/12/17 End: 12/31/19 Due: 12/31/20

The GD-2008 ALL Protocol for Childhood Acute Lymphoblastic Leukemia

Phase: N/A Priority: Normal
NCT ID: NCT00846703 Org: User:
Start: 07/31/08 End: 12/31/18 Due: 12/31/19

AI Assistant for Enhancing Colorectal Cancer Screening Among First-degree Relatives of Patients: a Randomized Trial

Phase: N/A Priority: Normal
NCT ID: NCT06710860 Org: User:
Start: 12/31/24 End: 01/31/26 Due: 01/31/27

PACE: PD-1 Antibody For dMMR/MSI-H Stage III Colorectal Cancer

Phase: N/A Priority: Normal
NCT ID: NCT05236972 Org: User:
Start: 01/01/22 End: 12/31/28 Due: 12/31/29

Oral Immunonutrition Therapy to Reduce Acute Toxicity After Neoadjuvant Chemoradiotherapy Pancreatic Cancer Patients

Phase: N/A Priority: Normal
NCT ID: NCT06736678 Org: User:
Start: 08/26/24 End: 09/30/25 Due: 09/30/26

Corneal Epithelium Repair and Therapy Using Autologous Limbal Stem Cell Transplantation

Phase: N/A Priority: Normal
NCT ID: NCT02148016 Org: User:
Start: 12/31/12 End: 09/30/14 Due: 09/30/15

Macular Buckle With Three-armed Silicone

Phase: N/A Priority: Normal
NCT ID: NCT02169635 Org: User:
Start: 05/31/13 End: 06/30/14 Due: 06/30/15

Combination of Tislelizumab and Chemoradiotherapy in Esophageal Cancer (EC-CRT-002)

Phase: N/A Priority: Normal
NCT ID: NCT05520619 Org: User:
Start: 09/15/22 End: 07/31/26 Due: 07/31/27

Validation of the Utility of Strabismus Intelligent Diagnostic System

Phase: N/A Priority: Normal
NCT ID: NCT04416776 Org: User:
Start: 09/01/19 End: 06/10/20 Due: 06/10/21

Tislelizumab Combined With SBRT for the Treatment of Head and Neck Squamous Cell Carcinoma

Phase: N/A Priority: Normal
NCT ID: NCT06673693 Org: User:
Start: 04/15/25 End: 12/31/29 Due: 12/31/30

Pemetrexed/Cisplatin With or Without Bevacizumab in Brain Metastases From Non Squamous Non-small Cell Lung Cancer

Phase: N/A Priority: Normal
NCT ID: NCT01951482 Org: User:
Start: 06/30/13 End: 06/30/20 Due: 06/30/21

Phase Ⅱ Study of HAIC of FOLFOX vs. Sorafenib in HCC Refractory to TACE

Phase: N/A Priority: Normal
NCT ID: NCT03722498 Org: User:
Start: 06/01/18 End: 03/22/21 Due: 03/22/22

NY-ESO-1-specific T Cell Receptor (TCR) T Cell in Sarcoma

Phase: N/A Priority: Normal
NCT ID: NCT03462316 Org: User:
Start: 05/21/18 End: 05/15/24 Due: 05/15/25

Efficacy of Modified Fruquintinib in Colorectal Cancer Liver Metastases: A Phase II Study

Phase: N/A Priority: Normal
NCT ID: NCT06018714 Org: User:
Start: 05/01/23 End: 08/01/26 Due: 08/01/27

Sugemalimab as Consolidation Therapy in Patients With LS-SCLC Following cCRT or sCRT

Phase: N/A Priority: Normal
NCT ID: NCT05623267 Org: User:
Start: 07/01/23 End: 03/31/27 Due: 03/31/28

Impact of a Printed Decision Aid on Cataract Surgery Choice

Phase: N/A Priority: Normal
NCT ID: NCT03525015 Org: User:
Start: 05/16/18 End: 10/30/19 Due: 10/30/20